Vanda Pharmaceuticals (VNDA) Earnings Date, Estimates & Call Transcripts → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free vnda Stock Alerts $4.48 -0.08 (-1.75%) (As of 04/25/2024 ET) Add Compare Share Share EarningsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 1EstimatedActual EPS (Feb. 7) -$0.04 Beat By $0.05 Consensus EPS (Feb. 7) -$0.09 Get Vanda Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for VNDA and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueVNDA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VNDA Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. Vanda Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.06) EPSNext Year EPS Consensus Estimate: ($0.33) EPSVNDA Earnings Date and InformationVanda Pharmaceuticals last released its earnings results on February 7th, 2024. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.05. The company had revenue of $45.27 million for the quarter, compared to the consensus estimate of $37 million. Vanda Pharmaceuticals has generated $0.05 earnings per share over the last year ($0.05 diluted earnings per share) and currently has a price-to-earnings ratio of 89.6. Earnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.06) to ($0.33) per share. Vanda Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off prior year's report dates.Read More Vanda Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/1/2024Estimated)------- 2/7/2024Q4 2023($0.09)($0.04)+$0.05($0.04)$37.00 million$45.27 million7/27/2023Q2 2023($0.13)$0.03+$0.16$0.03$49.00 million$46.06 million5/3/2023Q1 2023-$0.06+$0.06$0.06-$62.50 million2/8/2023Q4 2022$0.08$0.12+$0.04$0.12$67.60 million$64.48 million11/2/2022Q3 2022$0.10$0.06($0.04)$0.06$71.00 million$65.32 million8/3/2022Q2 2022$0.11$0.05($0.06)$0.05$67.00 million$64.39 million Get the Latest News and Ratings for VNDA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/5/2022Q1 2022($0.01)($0.11)($0.10)($0.11)$58.00 million$60.19 million 2/23/2022Q4 2021$0.09$0.12+$0.03$0.12$65.90 million$68.02 million 11/3/2021Q3 2021$0.20$0.14($0.06)$0.14$73.50 million$70.10 million 7/28/2021Q2 2021$0.17$0.17-$0.17$71.00 million$67.90 million 5/5/2021Q1 2021$0.14$0.15+$0.01$0.15$23.50 million$62.67 million Vanda Pharmaceuticals Earnings - Frequently Asked Questions When is Vanda Pharmaceuticals's earnings date? Vanda Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 1st, 2024 based off last year's report dates. Learn more on VNDA's earnings history. Did Vanda Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Vanda Pharmaceuticals (NASDAQ:VNDA) reported ($0.04) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.09) by $0.05. Learn more on analysts' earnings estimate vs. VNDA's actual earnings. How much revenue does Vanda Pharmaceuticals generate each year? Vanda Pharmaceuticals (NASDAQ:VNDA) has a recorded annual revenue of $192.64 million. How much profit does Vanda Pharmaceuticals generate each year? Vanda Pharmaceuticals (NASDAQ:VNDA) has a recorded net income of $2.51 million. VNDA has generated $0.05 earnings per share over the last four quarters. What is Vanda Pharmaceuticals's price-to-earnings ratio? Vanda Pharmaceuticals (NASDAQ:VNDA) has a trailing price-to-earnings ratio of 89.62. What is Vanda Pharmaceuticals's EPS forecast for next year? Vanda Pharmaceuticals's earnings are expected to decrease from ($0.06) per share to ($0.33) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Rigel Pharmaceuticals Earnings Verastem Earnings Gossamer Bio Earnings XOMA Earnings Regulus Therapeutics Earnings Emergent BioSolutions Earnings Lexicon Pharmaceuticals Earnings VBI Vaccines Earnings AnaptysBio Earnings OPKO Health Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:VNDA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
